

CURRICULUM VITAE

Adam J. Rose

1. PERSONAL INFORMATION



Date of Birth: 17/03/1974

Country of Birth: USA

Date of Immigration: 29/07/2019

ID number: 345457188

Nationality: Israeli and United States

Marital Status: Married

Number of Children: 4 (2006, 2008, 2011, 2011)

Permanent address: Hatsfira 13, Jerusalem

Cell: 055-500-1040

E-Mail: adam.rose@mail.huji.ac.il

2. HIGHER EDUCATION

1992-1996 Harvard University (USA), Music, BA. (magna cum laude).

1997-2001 University of Pennsylvania School of Medicine (USA), MD.

2005-2007 Boston University School of Public Health (USA), Health Services Research, MSc.
Supervisor: Prof. Dan Berlowitz.

Thesis Title: Understanding Uncontrolled Hypertension: Is It The Patient Or The Provider?

3. EMPLOYMENT

2001 - 2004 Resident in Internal Medicine (Montefiore Medical Center, Bronx, NY, USA – Academic Affiliate of Albert Einstein School of Medicine)

2004 - 2005 Chief Resident in Internal Medicine (Montefiore Medical Center, Bronx, NY, USA)

2005 - 2007 Resident in Preventive Medicine (Boston University School of Medicine, Boston, MA, USA)

2005 - 2008 Fellow in General Internal Medicine (Boston University School of Medicine,

Boston, MA, USA)

2008 - 2016 Clinician-Investigator, VA Center for Healthcare Organization and Implementation Research, Bedford, MA, USA

2008 - 2013 Assistant Professor of Medicine, Boston University School of Medicine, Boston, MA

2013 - 2020 Associate Professor of Medicine, Boston University School of Medicine, Boston, MA

2016 - 2019 Physician Policy Researcher, RAND Corporation, Boston, MA

2020 - present Associate Professor, Hebrew University School of Public Health, Jerusalem

4. APPOINTMENTS AT THE HEBREW UNIVERSITY

1.7.2020 - Associate Professor, Braun School of Public Health and Community Medicine

5. ADDITIONAL FUNCTIONS/TASKS AT THE HEBREW UNIVERSITY

2020 - present Reader of 6 Master's theses

2020 - present Member, PhD Committee, Braun School of Public Health.

2020-present Member, MPA Admissions Committee, Braun School of Public Health.

2021-present Member, International MPH Admissions Committee, Braun School of Public Health.

6. SERVICE IN OTHER ACADEMIC AND RESEARCH INSTITUTIONS

2021 Reader for PhD Dissertation, Ben Gurion University School of Public Health.

2022 Reader for PhD Dissertation, Ben Gurion University School of Public Health.

7. OTHER ACTIVITY

2006-2017 Society of General Internal Medicine, New England Region Annual Meeting – Chair of Abstract Review Committee

2007-2011 Boston University Responsible Conduct of Research Program. Faculty facilitator

2010-2013 Member, Research Ethics (Helsinki) Committee, Bedford VA Medical Center.

2012-2016 Chair, Bedford VA Medical Center Pharmacy and Therapeutics Committee

2012-2015	Technical Expert Consultant. National Committee for Quality Assurance (NCQA), Meaningful Use Project for Electronic Medical Records.
2012-2016	Member, Executive Advisory Board for VA Pharmacy Benefits Management Clinical Pharmacy Program Office.
2012-2016	Site Director, VA Physician Postdoctoral Fellowships, Bedford VAMC.
2013-2016	Director, Medication Optimization Group at the VA Center for Healthcare Organization and Implementation Research.
2013-2016	Co-Chair, VA Pharmacy Benefits Management Anticoagulation Subject Matter Experts Workgroup. Led the writing of a new VA National Anticoagulation Directive.
2014	VA State of the Art Conference on Quality Measurement. Co-Chair, Workgroup 1: "Making Quality Measures More Individualized and Clinically Meaningful".

Journal Editorships, Editorial Boards

2011-2020	Deputy Editor, <i>Journal of General Internal Medicine</i>
2022-present	Member of Editorial Board, <i>Hospitals</i>

Grant Reviews

2012-2016	VA Health Services Research and Development Grant Review Committee, permanent member
2012-2015	VA New England Career Development Award Review Committee
2019	Reviewer for National Institute of Arthritis and Musculoskeletal Skin Diseases, National Institutes of Health.
2019-present	Pears Foundation, Ad-Hoc Reviewer
2022	Chair, Israel Ministry of Health Digital Health RFA Review Panel
2022	Reviewer for Israeli Ministry of Innovation, Science and Technology, "All Sciences" RFA
2023	Member, Israel Science Foundation Health Sciences Review Panel

Conference Abstract Reviews

2007-2018	Society of General Internal Medicine National Meeting – Abstracts Reviewer
2009-2015	VA Health Services Research and Development National Meeting – Abstracts Reviewer
2019	AcademyHealth Annual Research Meeting – Abstracts Reviewer
2023	Israel Medical Association, Public Health Physicians Annual Conference. Abstracts Reviewer

Ad Hoc Journal Peer Reviews

2007-Present	Journal of General Internal Medicine
2007-Present	Substance Abuse
2008-Present	Journal of Thrombosis and Haemostasis
2008-Present	Pharmacy and Therapeutics
2008-Present	American Journal of Geriatric Pharmacotherapy
2009-Present	European Journal of Neurology

2009-Present	Expert Opinion on Pharmacotherapy
2009-Present	Hypertension
2009-Present	Journal of the American College of Cardiology
2009-Present	Reviews on Recent Clinical Trials
2009-Present	Chest
2009-Present	Age and Ageing
2009-Present	American Journal of Medicine
2009-Present	Thrombosis Journal
2009-Present	American Journal of Cardiovascular Drugs
2010-Present	American Journal of Care
2010-Present	BMC Cardiovascular Disorders
2010-Present	Clinical Epidemiology
2010-Present	Clinical Therapeutics
2010-Present	Diabetes Therapy
2010-Present	Diabetic Medicine
2010-Present	BMC Geriatrics
2010-Present	BMC Health Services Research
2010-Present	Thrombosis Research
2010-Present	Cardiology
2010-Present	Journal of the American Board of Family Medicine
2010-Present	International Journal of Nephrology and Renovascular Disease
2011-Present	JAMA
2011-Present	Thrombosis and Haemostasis
2011-Present	Circulation: Cardiovascular Quality and Outcomes
2011-Present	American Journal of the Medical Sciences
2011-Present	Archives of Public Health
2012-Present	Circulation
2012-Present	Annals of Internal Medicine
2012-Present	Hospital Practice
2012-Present	Journal of Health Communication
2012-Present	Pharmaceutics
2012-Present	American Journal of Cardiology
2013-Present	Comparative Effectiveness Research
2013-Present	International Journal of Pharmacy Practice
2013-Present	PLOS One
2014-Present	Patient Preference and Adherence
2014-Present	BMJ Open
2014-Present	Advances in Medical Sciences
2014-Present	Pharmacoepidemiology and Drug Safety
2014-Present	Journal of Medical Economics
2014-Present	Journal of Thrombosis and Thrombolysis
2016-Present	JAMA Cardiology
2016-Present	Joint Commission Journal on Quality and Patient Safety
2016-Present	JAMA Internal Medicine
2016-Present	Annals of Pharmacotherapy
2016-Present	PLOS Medicine
2016-Present	BMC Family Practice
2016-Present	Journal of Human Hypertension
2017-Present	Journal of Pharmacy Technology
2017-Present	Israel Journal of Health Policy Research
2017-Present	Research in Social and Administrative Pharmacy
2017-Present	BMJ Quality and Safety

2018-Present	Research and Practice in Thrombosis and Haemostasis
2018-Present	AMA Journal of Ethics
2018-Present	Journal of Gerontology: Medical Sciences
2020-Present	Journal of the American Heart Association
2021-Present	Health Literacy Research and Practice
2021-Present	Infection Control and Hospital Epidemiology
2021-Present	Annals of Epidemiology
2021-Present	Journal of Psychiatric Research
2021-Present	JAMA Network Open

Advisory Role/Affiliated Investigator:

2021-present	Affiliated Investigator, Center of Biomedical Research in Data Sciences (CHORDS), University of Massachusetts – Lowell
2021-present	Steering Committee Member, Israel Implementation Science and Policy Engagement Centre (IS-PEC) at Ben-Gurion University

8. PRIZES AND AWARDS

2006	First Prize, Boston University Medical Center Abstract Competition for Trainees. "Effectiveness of warfarin among patients with cancer"
2007	Third Prize, Boston University Medical Center Abstract Competition for Trainees. "The accuracy of clinician assessments of 'usual' blood pressure control"
2007	American Cancer Society, best cancer prevention and control poster by a trainee at 2007 meeting of American College of Preventive Medicine. "Predictors of aggressive therapy for nonmetastatic prostate carcinoma in Massachusetts from 1998-2002."
2007	Delta Omega Society. Honor society for students demonstrating academic excellence in public health degrees.
2007	Allen R. Meyers Memorial Award. Boston University School of Public Health, Department of Health Policy and Management. Given to a graduating masters-level student for academic excellence.
2009	Hamolsky Award for best abstract presentation by a junior faculty level investigator: Society of General Internal Medicine. "Treatment intensification improves blood pressure control both in adherent and non-adherent patients."
2009	Young Investigator Prize from the Journal of Thrombosis and Haemostasis for an excellent article by a first author age 35 or younger. "Warfarin dose management affects INR control."
2011	Clinician-Investigator of the Year, for outstanding career achievement in research by a junior faculty member. New England Region of the Society of General Internal Medicine.
2013	Boston University School of Medicine, Department of Medicine. Junior Faculty Mentoring

Award, presented to the junior faculty member who has contributed most to mentoring others.

- 2017 Presidential Early Career Award for Scientists and Engineers (PECASE). This is the highest honor bestowed by the United States government to outstanding scientists and engineers in the early stage of their independent research careers. Received for work done in the VA through 2014.
- 2020 Selected for mid-career faculty absorption program, administered by Israel's Ministry of Immigration and Absorption. This program provides partial salary support for five years to deserving mid-career faculty hired to Israeli universities after immigrating to Israel.
- 2022 Outstanding Teacher, Hebrew University. Top 10% of instructors based on student ratings for the academic year 2021-2022.

9. RESEARCH GRANTS

Current Grants

ISF. "Temporal Regularity of Primary Care Visits: A Novel Quality Measure". 2021-2024. Total Amount: 700,000 NIS. Relative share: all. Role: PI.

Israel Institute of Health Policy Research. "Validation of an improved case mix adjustment model for internal medicine wards in Israel". 2022-2023. Total Amount: 150,000 NIS. Relative share: all. Role: Corresponding Co-PI.

Israel Institute of Health Policy Research. "Telepsychiatry to enable expedited disposition of psychiatric emergencies". 2023-2024. Total Amount: 150,000 NIS. Relative share: all. Role: Corresponding Co-PI. Project approved by funder; funding pending Ministry of Health approval of project.

Completed Grants

United States Veterans Administration, Health Services Research and Development (VA HSR&D). "Quality of Oral Anticoagulation in the VA". 2008-2013. Total Amount: 1,000,000 USD. Relative share: all. Role: PI.

VA HSR&D. "Using Natural Language Processing to Identify Ischemic Stroke in the VHA". 2010-2011. Total Amount: 100,000 USD. Relative share: 50,000/100,000. Role: PI.

VA HSR&D. "Organization and Management of VHA Anticoagulation Clinics." 2010-2011. Total Amount: 100,000 USD. Relative share: all. Role: PI.

VA HSR&D. "Patient-Level Determinants of Oral Anticoagulation Control in the VHA". 2011-2013. Total Amount: 750,000 USD. Relative share: all. Role: PI.

VA HSR&D. "Patient-Level Predictors of Testosterone Prescribing in VA". 2014-2015. Total Amount: 30,000 USD. Relative share: all. Role: PI.

NIH - National Heart Lung and Blood Institute (NHLBI). "Effectiveness and Safety of Antithrombotic Strategies after Joint Replacement." 2011-2015. Total Amount: Approximately 2,000,000 USD. Relative share: 100,000/2,000,000. Role: Co-Investigator.

VA HSR&D. "Improving Anticoagulation Control in VISN 1." 2012-2016. Total Amount: 1,100,000 USD. Relative share: all. Role: PI.

VA HSR&D. "Clozapine Variation in the VA, a Qualitative Study". 2014-2015. Total Amount: 30,000 USD. Relative share: all. Role: Principal Investigator.

VA HSR&D. "Explaining Variation in Dabigatran Prescription Rates by VA Sites". 2015-2016. Total Amount: 100,000 USD. Relative share: all. Role: Principal Investigator.

NIH – NLBLI. "EHR Anticoagulants Pharmacovigilance". 2014-2021. PI: Hong Yu, University of Massachusetts. Total Amount: Approximately 5 million USD. Relative share: 150,000/5,000,000. Role: Co-Investigator.

Contract with NIH. "Outcome Performance Measure Development for Persons with Multiple Chronic Conditions." 2015-2017. Total Amount: Approximately 2,000,000 USD. Relative share: not relevant, team contract. Role: Co-Investigator.

GE Foundation. "Using Spatiotemporal Analyses to Understand the Opioid Epidemic in Massachusetts." 2016-2017. Total Amount: 200,000 USD. Relative share: 30,000/200,000. Role: Co-Investigator.

Contract with Assistant Secretary for Planning and Evaluation (ASPE), US Department of Health and Human Services. "Evaluation of Technology-Enabled Learning and Capacity Building Models." 2017-2018. Total Amount: 250,000 USD. Relative share: not relevant, team contract. Role: Co-PI.

Contract with US Centers for Medicare and Medicaid Services (CMS). "Evaluation of Million Hearts Model". 2017-2023 (left project in 2019 due to leaving RAND Corporation). Total Amount: 14,000,000 USD. Relative share: not relevant, team contract. Role: Task Lead.

Contract with US Department of Defense. "Military Health Related Behavior Survey of Active-Duty Service Members". 2017-2019. Total Amount: 9,000,000 USD. Relative share: not relevant, team contract. Role: Co-Investigator.

Contract with US Agency for Healthcare Research and Quality (AHRQ). "Environmental Scan and Analysis of Federally Funded Health Services Research and Primary Care Research". 2018-2019. Total Amount: 800,000 USD. Relative share: not relevant, team contract. Role: Task Lead

NIH – National Institute of Minority and Health and Health Disparities (NIMHD). "Exploring Performance Measures for the Care of Transgender Persons." 2018-2020. Total Amount: 400,000 USD. Relative share: 200,000/400,000. Role: Co-Principal Investigator.

10. PHARMA SUPPORTED GRANTS

none

11. TEACHING at HUJI

Supervisor or co-supervisor of master and doctoral degree students

a. Doctoral (PhD) degree students:

Years (period)	Name of Student	Subject	Academic Institute	Article Number
	none			

b. Master's degree students:

Years (period)	Name of Student	Subject	Academic Institute	Article Number
2020-ongoing	Shacharit Herman	Evaluating a new call system for nurses on the maternity ward (<i>co-supervisor with Asnat Walfisch</i>)	Hebrew University School of Public Health	
2020-2022	Hagar Pikkell	A qualitative study of Israeli healthcare workers who declined COVID vaccination	Hebrew University School of Public Health	
2020-ongoing	Shay Netzer	Implementing a parent-focused program to help children with autism and behavioral issues (<i>co-supervisor with Judah Koller</i>)	Hebrew University School of Education	
2021-ongoing	Reut Israeli	Evaluating Israel's quality measure set: what topics are being covered?	Hebrew University School of Public Health	
2022-ongoing	Karina Slobodkin	Treatment intensity for hypertension among survivors of acute kidney injury (<i>co-supervisor with Ron Wald</i>)	Hebrew University School of Public Health	
2022-ongoing	Shir Yaniv	Private and public medical practice in Israel (<i>co-supervisor with Shuli Brammli-Greenberg</i>)	Hebrew University School of Public Health	
2022-ongoing	Zohar Dahan	Disparities in waiting times among patients treated for breast cancer (<i>co-supervisor with Shani Paluch-Shimon</i>)	Hebrew University School of Public Health	
2022-ongoing	Ze'ev Fuchs	Impact of aggressive cancer therapy on likelihood of in-hospital death (<i>co-supervisor with Yakir Rotenberg</i>)	Hebrew University School of Public Health	
2022-ongoing	Yedidya Silverman	Effectiveness of an intervention to reduce falls in the elderly (<i>co-supervisor with Mark Clarfield</i>)	Hebrew University School of Public Health	

c. M.D. Thesis

Years	Name of	Subject	Academic	Article Number
-------	---------	---------	----------	----------------

(period)	Student		Institute	
	none			

d. Basic science residents' supervision

None

e. Supervision of Masters' Papers (MPH degree)

Years	Name of Student	Subject	Academic Institute	Article Number
2021	Husna Dafalla	Evaluating outcomes of home care for COVID-19 in South Sudan	HUJI School of Public Health	
2021	Jeanette Spitz	Trauma deserts in Chicago - Impact on long-term health related quality of life among those injured	HUJI School of Public Health	
2021	Luse Buinimasi	Process evaluation of tuberculosis treatment in Fiji - what is the quality of care being delivered?	HUJI School of Public Health	
2021	Sarah Aikite	Developing a set of quality of care measures for maternal and child care in Uganda	HUJI School of Public Health	
2021	Xiaolong Wu	A controlled trial comparing square dancing with tai chi among older Chinese citizens	HUJI School of Public Health	
2021	Vanessa Tabe	Low-cost health insurance and basic health care provided at early child care centers in Cameroon	HUJI School of Public Health	
2022	Ashley Castillo	Implementing and evaluating home care for at-risk elders in Guatemala	HUJI School of Public Health	
2022	Vasana H Damon	A program to reduce catheter-associated UTI at a teaching hospital in Guyana	HUJI School of Public Health	
2022	Daniel Onen	A new approach to mental health treatment among refugees in Uganda	HUJI School of Public Health	
2022	Jessica Richman	Implementing and evaluating restorative justice in an urban school district in California	HUJI School of Public Health	
2022	Miriam Markfort	A preventive dental intervention in Madagascar	HUJI School of Public Health	

f. Post-doctoral Fellows

Years	Name of Fellow	Subject	Academic Institute	Article Number
2022-ongoing	Maram Hazen	How do team members work together to ensure regular follow-up for adults with chronic disease at Leumit clinics?	HUJI School of Public Health	
2022-ongoing	Ligat Shalev	Implementing and evaluating a program to reduce emergency room time among patients seen for psychiatric emergencies	HUJI School of Public Health	

g. Mentorship for Postgraduate Career Development Grants

Years	Name of Mentee	Subject	Funder	My Role	Article Number
2022-ongoing	Enjeh Fombo (Graduate, HUJI Public Health)	Obesity Among Children with Disabilities (Cameroon)	Royal Society of Tropical Medicine and Hygiene	Faculty Mentor	

Courses taught**a. Bachelor's degree courses**

none

b. *Master's degree courses*

2020-present 95025 "Organization of Medical Care"
 2021-present 95258 "Research Forum for MPH Thesis"
 2022-present 95253 "Monitoring and Evaluation of Public Health Programs"

c. *Other*Guest Lectures

Location	Instructor/Course	Lecture Title	Years
Boston University School of Public Health	Dan Berlowitz/PM837 Quality of Care Measurement	"Quality of Care Measurement in Anticoagulation"	2011, 2012, 2013, 2014, 2015
Hebrew University School of Public Health	Avi Israeli, 98804 Planning and Evaluation of Health Services	"The Role of Primary Care in the Health System" (in Hebrew)	2021
Hebrew University School of Public Health	Avi Israeli, 98804 Planning and Evaluation of Health	"Implementation Science" (in Hebrew)	2021

	Services		
--	----------	--	--

LIST OF PUBLICATIONS

ISI H-INDEX: 29

CITATIONS:

2375

GOOGLE SCHOLAR H-INDEX: 39

CITATIONS: 3943

DOCTORAL DISSERTATION

Not applicable.

BOOKS

None

BOOKS EDITED

None

PEER-REVIEWED ARTICLES

1. **Rose AJ (S)**, Stein MR (C), Arnsten JH (C), Saitz R (PI). Teaching Internal Medicine Resident Physicians about Alcoholics Anonymous: A Pilot Study of an Educational Intervention. *Subst Abuse*. 2006;27:5-11. DOI: 10.1300/J465v27n03_02. 3.984; 13/21 (SCIE); 17/37 (SSCI); 11
2. **Rose AJ (S)**, Backus BM (T), Gershman ST (C), Santos P (C), Ash AS (C), Battaglia TA (PI). Predictors of Aggressive Therapy for Nonmetastatic Prostate Carcinoma in Massachusetts from 1998-2002. *Med Care*. 2007;45:440-7. DOI: 10.1097/01.mlr.0000257144.29928.f0. 3.178; 49/109 (SCIE); 34/88 (SSCI); 109/210 (SCIE); 6
3. **Rose AJ (S)**, Sharman JP (C), Ozonoff A (C), Henault LE (T), Hylek EM (PI). Effectiveness of Warfarin among Patients with Cancer. *J Gen Intern Med*. 2007;22:997-1002. DOI: 10.1007/s11606-007-0228-y. 6.473; 11/109; 31/172; 45
4. **Rose AJ (S)**, Berlowitz DR (C), Orner MB (T), Kressin NR (PI). Understanding Uncontrolled Hypertension: Is It the Patient or the Provider? *J Clin Hypertens*. 2007;9:937-43. DOI: 10.1111/j.1524-6175.2007.07332.x. 2.885; 43/67; 16
5. **Rose AJ (S)**, Shimada SL (S), Rothendler JA (C), Reisman JI (T), Glassman PA (C), Berlowitz DR (C), Kressin NR (PI). The Accuracy of Clinician Perceptions of 'Usual' Blood Pressure Control. *J Gen Intern Med*. 2008;23:180-3. DOI: 10.1007/s11606-007-0464-1. 6.473; 11/109; 31/172; 22
6. **Rose AJ* (S)**, Sacks NC* (S), Deshpande AP (S), Griffin SY (S), Cabral HJ (C), Kazis LE (PI). Single Change Items Did Not Measure Change in Quality of Life. *J Clin Epidemiol*. 2008;61:603-8. *Shared First Authorship. DOI: 10.1016/j.jclinepi.2007.07.010. 7.407; 9/109; 28/210; 9
7. **Rose AJ (S)**, Ozonoff A (C), Henault LE (T), Hylek EM (PI). Warfarin for Atrial Fibrillation in Community-Based Practise. *J Thromb Haemost*. 2008;6:1647-54. DOI: 10.1111/j.1538-7836.2008.03075.x. 16.041; 5/78; 3/67; 74
8. **Rose AJ (S)**, Ozonoff A (C), Berlowitz DR (C), Henault LE (T), Hylek EM (PI). Warfarin Dose Management affects INR Control. *J Thromb Haemost*. 2009;7:94-101. DOI: 10.1111/j.1538-7836.2008.03199.x. 16.041; 5/78; 3/67; 31
9. **Rose AJ (S)**, Hermos JA (C), Frayne SM (C), Pogach LM (C), Berlowitz DR (C), Miller DR (PI). Does Opioid Therapy Affect Quality of Care for Diabetes Mellitus? *Am J Manag Care*. 2009;15:217-

24. PMID:19355794.
3.247; 48/109 (SCIE); 33/88 (SSCI); 73/172 (SCIE); 16
10. Berz JP (S), Johnston KT (S), Backus B (T), Doros G (C), **Rose AJ (C)**, Pierre S (C), Battaglia TA (PI). The Influence of Black Race on Treatment and Mortality for Early Stage Breast Cancer. *Med Care*. 2009;47:986-92. DOI: 10.1097/MLR.0b013e31819e1f2b.
3.178; 49/109 (SCIE); 34/88 (SSCI); 109/210 (SCIE); 24
11. **Rose AJ (S)**, Berlowitz DR (C), Manze M (T), Orner MB (T), Kressin NR (PI). Comparing Methods of Measuring Treatment Intensification in Hypertension Care. *Circ-Cardiovasc Qual Outcomes*. 2009;2:385-91. DOI: 10.1161/CIRCOUTCOMES.108.838649.
8.271; 24/143; 20
12. **Rose AJ (S)**, Berlowitz DR (C), Manze M (T), Orner MB (T), Kressin NR (PI). Intensifying Therapy for Hypertension despite Suboptimal Adherence. *Hypertension*. 2009;54:524-9. DOI: 10.1161/HYPERTENSIONAHA.109.133389.
9.897; 8/67; 32
13. **Rose AJ (S)**, Ozonoff A (C), Grant RW (C), Henault LE (T), Hylek EM (PI). Epidemiology of Subtherapeutic Anticoagulation in the United States. *Circ Cardiovasc Qual Outcomes*. 2009;2:591-7. DOI: 10.1161/CIRCOUTCOMES.109.862763.
8.271; 24/143; 44
14. **Rose AJ (S)**, Ozonoff A (C), Henault LE (T), Hylek EM (C). Anticoagulation for Valvular Heart Disease in Community-Based Practice. *Thromb Haemost*. 2010;103:329-37. DOI: 10.1160/TH09-07-0450.
6.830; 18/78; 12/67; 3
15. Manze M (S), **Rose AJ (C)**, Orner MB (T), Berlowitz DR (C), Kressin NR (PI). Understanding Racial Disparities in Treatment Intensification for Hypertension Management. *J Gen Intern Med*. 2010;25:819-25. DOI: 10.1007/s11606-010-1342-9.
6.473; 11/109; 31/172; 22
16. **Rose AJ (PI)**, Hylek EM (C), Ozonoff A (C), Ash AS (C), Reisman JI (T), Berlowitz DR (C). Patient Characteristics Associated with Oral Anticoagulation Control: Results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). *J Thromb Haemost*. 2010;8:2182-91. DOI: 10.1111/j.1538-7836.2010.03996.x.
16.041; 5/78; 3/67; 155
17. **Rose AJ (PI)**, Hylek EM (C), Ozonoff A (C), Ash AS (C), Reisman JI (T), Berlowitz DR (C). Risk-Adjusted Percent Time in Therapeutic Range as a Quality Indicator for Outpatient Oral Anticoagulation: Results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). *Circ-Cardiovasc Qual Outcomes*. 2011;4:22-29. DOI: 10.1161/CIRCOUTCOMES.110.957738.
8.271; 24/143; 89
18. **Rose AJ* (C)**, Glickman ME* (C), D'Amore MM (T), Orner MB (T), Berlowitz DR (C), Kressin NR (PI). Effects of Daily Adherence to Anti-Hypertensive Medication on Blood Pressure Control. *J Clin Hypertens*. 2011;13:416-421. *Shared First Authorship. DOI: 10.1111/j.1751-7176.2011.00427.x.
2.885; 43/67; 20
19. **Rose AJ (PI)**, Ozonoff A (C), Berlowitz DR (C), Ash AS (C), Reisman JI (T), Hylek EM (C). Re-Examining the Recommended Follow-Up Interval after an In-Range INR Value: Results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). *Chest*. 2011;140:359-365. DOI: 10.1378/chest.10-2738.
11.393; 5/35; 6/66; 21
20. **Rose AJ (PI)**, Hylek EM (C), Berlowitz DR (C), Ash AS (C), Reisman JI (T), Ozonoff A (C). Prompt Repeat Testing after Out-of-Range INR Values: A Quality Indicator for Anticoagulation Care. *Circ-Cardiovasc Qual Outcomes*. 2011;4:276-282. DOI: 10.1161/CIRCOUTCOMES.110.960096.
8.271; 24/143; 27
21. **Rose AJ (PI)**, Hylek EM (C), Ozonoff A (C), Ash AS (C), Reisman JI (T), Callahan P (C), Gordon M (C), Berlowitz DR (C). Relevance of Current Guidelines for Organizing an Anticoagulation

- Clinic. *Am J Manag Care*. 2011;17:284-289. PMID: 21615198.
3.247; 48/109 (SCIE); 33/88 (SSCI); 73/172 (SCIE); 1.
22. **Rose AJ (PI)**, Berlowitz DR (C), Ash AS (C), Ozonoff A (C), Hylek EM (C), Goldhaber-Fiebert JD (PI). The Business Case for Quality Improvement: Oral Anticoagulation for Atrial Fibrillation. *Circ Cardiovasc Qual Outcomes*. 2011;4:416-424. DOI: 10.1161/CIRCOUTCOMES.111.960591. 8.271; 24/143; 29
 23. Marrast L (S), Evans M (S), Ozonoff A (C), Henault L (T), **Rose AJ (PI)**. Using highly variable warfarin dosing to identify patients at risk for adverse events. *Thromb J*. 2011;9:14. DOI: 10.1186/1477-9560-9-14. 5.509; 28/78; 19/67; 1
 24. **Rose AJ (PI)**, Petrakis BA (T), Callahan P (C), Mambourg S (C), Patel D (C), Hylek EM (C), Bokhour BG (C). Organizational Characteristics of High- and Low-Performing Anticoagulation Clinics in the Veterans Health Administration. *Health Serv Res*. 2012;47:1541-1560. DOI: 10.1111/j.1475-6773.2011.01377.x. 3.734; 35/109 (SCIE); 21/88 (SSCI); 20
 25. **Rose AJ (PI)**, Berlowitz DR (C), Miller DR (C), Hylek EM (C), Ozonoff A (C), Zhao S (T), Reisman JI (T), Ash AS (C). INR Targets and Site-Level Anticoagulation Control: Results from the Veterans Affairs Study to Improve Anticoagulation (VARIA). *J Thromb Haemost*. 2012;10:590-595. DOI: 10.1111/j.1538-7836.2012.04649.x. 16.041; 5/78; 3/67; 11
 26. Rothendler JI (PI), **Rose AJ (C)**, Reisman JI (T), Berlowitz DR (C), Kazis LE (C). Choices in the use of ICD-9 codes to identify stroke risk factors can affect the apparent population-level risk factor prevalence and distribution of CHADS2 scores. *Am J Cardiovasc Dis*. 2012;2:184-191. PMID: 22937488. X; X; 25
 27. **Rose AJ (PI)**, Miller DR (C), Ozonoff A (C), Berlowitz DR (C), Ash AS (C), Zhao S (T), Reisman JI (T), Hylek EM (C). Gaps in monitoring during oral anticoagulation: Insights into care transitions, monitoring barriers, and medication nonadherence. *Chest*. 2013;143:751-757. DOI: 10.1378/chest.12-1119. 11.393; 5/35; 6/66; 35
 28. Jasuja GK (S), Reisman JI (T), Miller DR (C), Berlowitz DR (C), Hylek EM (C), Ash AS (C), Ozonoff A (C), Zhao S (T), **Rose AJ (PI)**. Identifying Major Hemorrhage with Automated Data: Results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). *Thromb Res*. 2013;131:31-36. DOI: 10.1016/j.thromres.2012.10.010. 10.409; 11/78; 6/67; 12
 29. Jasuja GK (S), Travison TG (C), Davda M (C), Murabito JM (C), Basaria S (C), Zhang A (C), Kushnir MM (C), Rockwood AL (C), Meikle W (C), Pencina MJ (C), Coviello A (C), **Rose AJ (C)**, D'Agostino R (C), Vasan RS (C), Bhasin S (PI). Age Trends in Estradiol and Estrone Levels Measured Using Liquid Chromatography Tandem Mass Spectrometry in Community-Dwelling Men of the Framingham Heart Study. *J Gerontol A Biol Sci Med Sci*. 2013;68:733-40. DOI: 10.1093/gerona/gls216. 6.591; 13/54 (SCIE); 5/37 (SSCI); 56
 30. Jasuja GK (S), Travison TG (C), Davda M (C), **Rose AJ (C)**, Zhang A (C), Kushnir MM (C), Rockwood AL (C), Meikle W (C), Coviello A (C), D'Agostino R (C), Vasan RS (C), Bhasin S (PI). Circulating Estrone Levels are Associated Prospectively with Diabetes Risk in Men of the Framingham Heart Study. *Diabetes Care*. 2013;36:2591-6. DOI: 10.2337/dc12-2477. 17.155; 6/146; 21
 31. Jasuja GK (S), Bhasin S (C), Reisman JI (C), **Rose AJ (PI)**. Wide Variations in the Use of Testosterone Therapy among VA Facilities. *Am J Pharm Benefits*. 2013;5:e122-e128. X; X; 1
 32. Efird LM (S), Miller DR (C), Ash AS (C), Berlowitz DR (C), Ozonoff A (C), Zhao S (T), Reisman JI (T), Jasuja GK (C), **Rose AJ (PI)**. Identifying the Risks of Anticoagulation in Patients with Substance Abuse. *J Gen Intern Med*. 2013;28:1333-9. DOI: 10.1007/s11606-013-2453-x. 6.473; 11/109; 31/172; 10

33. Cancino RS (S), Hylek EM (C), Reisman JI (T), **Rose AJ (PI)**. Comparing Patient-Level and Site-Level Anticoagulation Control as Predictors of Adverse Events. *Thromb Res*. 2014;133:652-6. DOI: 10.1016/j.thromres.2014.01.013.
10.409; 11/78; 6/67; 25
34. Paradise HT (S), Berlowitz DR (C), Ozonoff A (C), Miller DR (C), Hylek EM (C), Ash AS (C), Jasuja GK (C), Zhao S (T), Reisman JI (T), **Rose AJ (PI)**. Outcomes of Anticoagulation Therapy in Patients with Mental Health Conditions. *J Gen Intern Med*. 2014;29:855-61. DOI: 10.1007/s11606-014-2784-2.
6.473; 11/109; 31/172; 26
35. Razouki Z (S), Ozonoff A (C), Zhao S (T), **Rose AJ (PI)**. Pathways to poor anticoagulation control. *J Thromb Haemost*. 2014;12:628-34. DOI: 10.1111/jth.12530.
16.041; 5/78; 3/67; 22
36. Efird LM (S), Mishkin DS (C), Berlowitz DR (C), Ash AS (C), Hylek EM (C), Ozonoff A (C), Reisman JI (T), Zhao S (T), Jasuja GK (C), **Rose AJ (PI)**. Stratifying the Risks of Oral Anticoagulation in Patients with Liver Disease. *Circ-Cardiovasc Qual Outcomes*. 2014;7:461-7. DOI: 10.1161/CIRCOUTCOMES.113.000817. 8.271; 24/143; 38
37. Kim B (S), Shaikh OA (C), **Rose AJ (PI)**. Examining warfarin dosing decisions to improve anticoagulation management. *J Pharm Technol*. 2014; 30(5):168-174. DOI: 10.1177/8755122514537042.
X; X; 1
38. Ozkaynak M (S), Johnson SA (C), Tulu B (C), Donovan JL (C), Kanaan AO (C), **Rose A (PI)**. Exploring the effect of complex patients on care delivery tasks. *Int J Health Care Qual Assur*. 2014;28:494-509. DOI: 10.1108/IJHCQA-11-2014-0105.
X; X; 8
39. Razouki Z (S), Ozonoff A (C), Zhao S (T), Jasuja GK (C), **Rose AJ (PI)**. Improving quality measurement for anticoagulation: Adding international normalized ratio variability to percent time in therapeutic range (TTR). *Circ-Cardiovasc Qual Outcomes*. 2014;7:664-9. DOI: 10.1161/CIRCOUTCOMES.114.000804.
8.271; 24/143; 44
40. McCullough MB (C), Solomon JL (C), Petrakis BA (T), Park AM (C), Ourth H (C), Morreale AP (C), **Rose AJ (PI)**. Balancing Collaborative and Independent Practice Roles in Clinical Pharmacy: A Qualitative Research Study. *Ann Pharmacother*. 2015;49:189-95. DOI: 10.1177/1060028014561473.
3.463; 148/279; 3
41. Rao SR (C), Reisman JI (T), Kressin NR (C), Berlowitz DR (C), Ash A (C), Ozonoff A (C), Miller DR (C), Hylek EM (C), Zhao S (T), **Rose AJ (PI)**. Explaining Racial Disparities in Anticoagulation Control: Results from a Study of Patients at Veterans Administration (VA). *Am J Med Qual*. 2015;30:214-22. DOI: 10.1177/1062860614526282.
1.200; 105/109; 14
42. McCullough MB (C), Chou AF (C), Solomon JL (C), Petrakis BA (T), Kim B (C), Park AM (C), Benedict AJ (C), Hamilton AB (C), **Rose AJ (PI)**. The interplay of contextual elements in implementation: an ethnographic case study. *BMC Health Serv Res*. 2015;15:62. DOI: 10.1186/s12913-015-0713-7.
2.908; 63/109; 19
43. Razouki Z (S), Burgess JF (C), Ozonoff A (C), Zhao S (T), Berlowitz D (C), **Rose AJ (PI)**. Improving Anticoagulation Measurement: Novel Warfarin Composite Measure. *Circ-Cardiovasc Qual Outcomes*. 2015;8:600-7. DOI: 10.1161/CIRCOUTCOMES.115.001789.
8.271; 24/143; 8
44. Kim EJ (S), Ozonoff A (C), Hylek EM (C), Berlowitz DR (C), Ash AS (C), Miller DR (C), Zhao S (T), Reisman JI (T), Jasuja GK (C), **Rose AJ (PI)**. Predicting outcomes among patients with atrial fibrillation and heart failure receiving anticoagulation with warfarin. *Thromb Haemost*.

- 2015;114:70-77. DOI: 10.1160/TH14-09-0754.
6.830; 18/78; 12/67; 10
45. Shore S (S), Ho PM (PI), Lambert-Kerzner A (C), Glorioso TJ (C), Carey EP (C), Cunningham F (C), Longo L (C), Jackevicius C (C), **Rose A (C)**, Turakhia MP (PI). Site-level variation in and practices associated with dabigatran adherence. *JAMA-J Am Med Assoc*. 2015;313:1443-50. DOI: 10.1001/jama.2015.2761.
157.375; 3/172; 99
 46. Jasuja GK, (PI) Bhasin S (C), Reisman JI (C), Berlowitz DR (C), **Rose AJ (PI)**. Ascertainment of Testosterone Prescribing Practices in the VA. *Med Care*. 2015;52:746-52. DOI: 10.1097/MLR.0000000000000398.
3.178; 49/109 (SCIE); 34/88 (SSCI); 109/210 (SCIE); 33
 47. **Rose AJ (PI)**, Delate T (C), Ozonoff A (C), Witt DM (PI). Comparison of the Abilities of Summary Measures of International Normalized Ratio Control to Predict Clinically Relevant Bleeding. *Circ-Cardiovasc Qual Outcomes*. 2015;8:524-31. DOI: 10.1161/CIRCOUTCOMES.115.001768.
8.271; 24/143; 10
 48. **Rose AJ (PI)**, Reisman JI (T), Razouki Z (C), Ozonoff A (C). Percent Time in Range with Warfarin as a Performance Measure: How Long a Sampling Frame Is Needed? *Jt Comm J Qual Patient Saf*. 2015;41:561-8. DOI: 10.1016/S1553-7250(15)41073-6.
X; X; 5
 49. McCullough MB (C), Petrakis BA (T), Gillespie CK (C), Solomon JL (C), Park AM (C), Ourth H (C), Morreale AP (C), **Rose AJ (PI)**. Knowing the Patient: A qualitative study on care-taking and the clinical pharmacist-patient relationship. *Res Soc Admin Pharm*. 2016;12:78-90. DOI: 10.1016/j.sapharm.2015.04.005.
3.348; 78/182 (SSCI); 22
 50. **Rose AJ (PI)**, Phibbs CS (C), Uyeda L (T), Su P (T), Edson R (T), Shih MC (T), Jacobson A (C), Matchar DB (C). Does distance modify the effect of self-testing in oral anticoagulation? *Am J Manag Care*. 2016;22:65-71. PMID:26799126.
3.247; 48/109 (SCIE); 33/88 (SSCI); 73/172 (SCIE); 1
 51. Kuhn H (S), Park A (C), Kim B (C), Lukesh W (C), **Rose A (PI)**. Proportion of work appropriate for pharmacy technicians in anticoagulation clinics. *Am J Health Syst Pharm*. 2016;73:322-7. DOI: 10.2146/ajhp150272. 2.980; 180/279; 7
 52. Goren JL (PI), **Rose AJ (C)**, Engle RL (C), Smith EG (C), Christopher M (C), Rickles NM (C), Semla T (C), McCullough MB (PI). Organizational characteristics of Veterans Affairs clinics with high and low utilization of clozapine. *Psychiat Serv*. 2016;67:1189-96. DOI: 10.1176/appi.ps.201500506.
4.157; 16/88 (SSCI); 74/155 (SCIE); 82/210 (SCIE); 56/182 (SSCI); 10
 53. Goren JL (PI), **Rose AJ (C)**, Smith EG (C), Ney JP (PI). The business case for expanded clozapine utilization. *Psychiat Serv*. 2016;67:1197-1205. DOI: 10.1176/appi.ps.201500507.
4.157; 16/88 (SSCI); 74/155 (SCIE); 82/210 (SCIE); 56/182 (SSCI); 15
 54. Razouki ZA (S), Knighton T (C), Martinello R (C), Hirsch PR (C), McPhaul KM (C), **Rose AJ (C)**, McCullough MB (PI). Organizational factors associated with health care provider (HCP) influenza campaigns in the Veterans Health Care System: A qualitative study. *BMC Health Serv Res*. 2016;16:211. DOI: 10.1186/s12913-016-1462-y.
2.908; 63/109; 5
 55. **Rose AJ (PI)**, Reisman JI (T), Allen AL (C), Miller DR (C). Potentially inappropriate prescribing of direct-acting oral anticoagulants in the Veterans Health Administration. *Am J Pharm Benefits*. 2016;8:e75-e80.
X; X; 2
 56. Ambrus D (S), Reisman JI (T), **Rose AJ (PI)**. The Impact of New-Onset Cancer Among Veterans Who Are Receiving Warfarin for Atrial Fibrillation and Venous Thromboembolism. *Thromb Res*. 2016;14:21-6. DOI: 10.1016/j.thromres.2016.05.028.
10.409; 11/78; 6/67; 16

57. Mantha S (PI), Moll S (C), Hilden P (C), Devlin S (C), **Rose A (C)**. The patterns of anticoagulation control and risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation: comment. *J Thromb Haemost*. 2016;14:2083-4. DOI: 10.1111/jth.13420. 16.041; 5/78; 3/67; 0
58. Orkaby AR (S), Ozonoff A (C), Reisman JI (T), Miller DR (C), Zhao S (T), **Rose AJ (PI)**. Continued use of warfarin in veterans with atrial fibrillation following dementia diagnosis. *J Am Geriatr Soc*. 2017;65:249-56. DOI: 10.1111/jgs.14573. 7.538; 10/54 (SCIE); 2/37 (SSCI); 29
59. Jasuja GK (PI), Bhasin S (C), Reisman JI (T), Hanlon JT (C), Miller DR (C), Morreale AP (C), Pogach LM (C), Cunningham FE (C), Park A (C), Berlowitz DR (C), **Rose AJ (PI)**. Who Gets Testosterone? Patient Characteristics Associated with Testosterone Prescribing in the Veteran Affairs System: A Cross-Sectional Study. *J Gen Intern Med*. 2017;32:304-311. DOI: 10.1007/s11606-016-3940-7. 6.473; 11/109; 31/172; 21
60. Jasuja GK (S), Trivison TG (C), Murabito JM (C), Davda MN (C), **Rose AJ (C)**, Basaria S (C), Coviello A (C), Vasan RS (C), D'Agostino R (C), Bhasin S (PI). Circulating estrogen levels and self-reported health and mobility limitation in community-dwelling men of the Framingham Heart Study. *J Gerontol A Biol Sci Med Sci*. 2017;72:1137-42. doi: 10.1093/gerona/glw197. DOI: 10.1093/gerona/glw197. 6.591; 13/54 (SCIE); 5/37 (SSCI); 1
61. **Rose AJ (PI)**, Park A (C), Gillespie C (C), Van Deusen Lukas C (C), Ozonoff A (C), Petrakis BA (T), Reisman JI (T), Borzecki AM (C), Benedict AJ (C), Lukesh WN (C), Schmoke TJ (C), Jones EA (C), Morreale AP (C), Ourth HL (C), Schlosser JE (C), Mayo-Smith MF (C), Allen AL (C), Witt DM (C), Helfrich CD (C), McCullough MB (C). Results of a regional effort to improve warfarin management. *Ann Pharmacother*. 2017;51:373-9. DOI: 10.1177/1060028016681030. 3.463; 148/279; 3
62. Kim EJ (S), Kim T (C), Pasche-Orlow MK (PI), **Rose AJ (C)**, Hanchate AD (PI). Disparities in hypertension associated with limited English proficiency. *J Gen Intern Med*. 2017;32:632-9. DOI: 10.1007/s11606-017-3999-9. 6.473; 11/109; 31/172; 44
63. Jasuja GK (PI), Bhasin S (C), **Rose AJ (C)**, Reisman JI (T), Hanlon JT (C), Miller DR (C), Morreale AP (C), Pogach LM (C), Cunningham FE (C), Park A (C), Wiener RS (C), Gifford AL (C), Berlowitz DR (C). Provider and site-level determinants of testosterone prescribing in the Veterans Healthcare System. *J Clin Endocrinol Metab*. 2017;102:3226-3233. DOI: 10.1210/jc.2017-00468. 6.134; 32/146; 8
64. White Hughto JM (PI), **Rose AJ (C)**, Pachankis JE (C), Reisner SM (C). Barriers to Gender Transition-Related Healthcare: Identifying Underserved Transgender Adults in Massachusetts. *Transgender Health*. 2017;2:107-118. DOI: 10.1089/trgh.2017.0014. 4.427; 36/131 (SSCI); 76/210 (SCIE); 48/182 (SSCI); 8/46 (SSCI); 61
65. McCullough MB (C), Gillespie C (C), Petrakis BA (T), Jones EA (C), Park AM (C), Lukas CV (C), **Rose AJ (PI)**. Forming and activating an internal facilitation group for successful implementation: A qualitative study. *Res Soc Adm Pharm*. 2017;13:1014-1027. PMID: 28434918. DOI: 10.1016/j.sapharm.2017.04.007. 3.348; 78/182 (SSCI); 7
66. Helfrich CD (PI), **Rose AJ (C)**, Hartmann CW (C), van Bodegom L (C), Graham ID (C), Wood S (C), Majerczyk B (C), Good CB (C), Pogach LM (C), Ball SL (C), Au DH (PI), Aron DC (C). How the dual-process model of human cognition can inform efforts to de-implement ineffective and harmful practices: A preliminary model of unlearning and substitution. *J Eval Clin Pract*. 2018;24:198-205. DOI: 10.1111/jep.12855. 2.336; 76/109; 27/31; 105/172; 53

67. Lavelle TA (C), **Rose AJ (C)**, Timbie JW (C), Setodji CM (C), Wensky SG (C), Giuriceo KD (C), Friedberg MW (C), Malsberger R (T), Kahn KL (PI). Utilization of health care services among Medicare beneficiaries who visit federally qualified health centers. *BMC Health Serv Res*. 2018;18:41. DOI: 10.1186/s12913-018-2847-x. 2.908; 63/109; 7
68. Jasuja GK (PI), Bhasin S (C), **Rose AJ (C)**, Reisman JI (T), Skolnik A (C), Berlowitz DR (C), Gifford AL (C). Use of Testosterone in Men Infected with Human Immunodeficiency Virus in the Veterans Healthcare System. *AIDS Care*. 2018; 30(10):1207-1214. DOI: 10.1080/09540121.2018.1447080. 1.887; 74/88 (SSCI); 91/148 (SSCI); 149/182 (SSCI); 5
69. Kim D (S), Lee KM (C), Freiman MR (C), Powell WR (C), Klings ES (C), Rinne S(C), Miller D (C), **Rose AJ (C)**, Wiener RS (PI). Phosphodiesterase-5 inhibitor Therapy for Pulmonary Hypertension in the United States: Actual versus Recommended Use. *Ann Am Thorac Soc*. 2018;15:693-701. DOI: 10.1513/AnnalsATS.201710-762OC. 8.785; 10/66; 16
70. Gillespie C (C), **Rose AJ (C)**, Petrakis BA (C), Park A (C), McCullough MB (PI). Qualitative study of patient experiences of responsibility in warfarin therapy. *Am J Health-Syst Pharm*. 2018;75(22):1798-1804. 2.980; 180/279; 3
71. **Rose AJ (PI)**, Bernson D (C), Chui K (C), Land T (C), Walley AY (C), LaRochelle MR (C), Stein BD (C), Stopka TJ (PI). Potentially Inappropriate Opioid Prescribing, Overdose, and Mortality in Massachusetts, 2011-2015. *J Gen Intern Med*. 2018;33:1512-1519. DOI: 10.1007/s11606-018-4532-5. 6.473; 11/109; 31/172; 39
72. **Rose AJ (C)**, Bayliss E (C), Huang W (C), Baseman L (T), Butcher E (T), Garcia RE (T), Edelen MO (PI). Evaluating the PROMIS-29 v2.0 for use among older adults with multiple chronic conditions. *Qual Life Res*. 2018;27:2935-2944. DOI: 10.1007/s11136-018-1958-5. 3.440; 43/109 (SCIE); 29/88 (SSCI); 100/210 (SCIE); 72/182 (SSCI); 31
73. Jasuja GK (PI), Ameli O (C), Miller DR (C), Land T (C), Bernson D (C), **Rose AJ (C)**, Berlowitz DR (C), Smelson DA (C). Overdose Risk for Veterans Receiving Opioids from Multiple Sources. *Am J Manag Care*. 2018;24:536-540. 3.247; 48/109 (SCIE); 33/88 (SSCI); 73/172 (SCIE); 8
74. Huang W (C), **Rose AJ (C)**, Bayliss E (C), Baseman L (T), Butcher E (T), Garcia RE (C), Edelen MO (PI). Adapting summary scores for the PROMIS-29 v2.0 for use among older adults with multiple chronic conditions. *Qual Life Res*. 2019;28:199-210. doi: 10.1007/s11136-018-1988-z. 3.440; 43/109 (SCIE); 29/88 (SSCI); 100/210 (SCIE); 72/182 (SSCI); 4
75. Done N (S), Roy AM (C), Yuan Y (C), Pizer SD (C), **Rose AJ (C)**, Prentice JC (PI). Guideline-Concordant Initiation of Oral Anticoagulant Therapy for Stroke Prevention in Older Veterans with Atrial Fibrillation Eligible for Medicare Part D. *Health Serv Res*. 2019;54:128-138. DOI: 10.1111/1475-6773.13079. 3.734; 35/109 (SCIE); 21/88 (SSCI); 4
76. Jasuja GK (PI), Reisman JI (T), Wiener RS (C), Christopher ML (C), **Rose AJ (C)**. Gender differences in prescribing of zolpidem in the Veterans Health Administration. *Am J Manag Care*. 2019;25:e58-e65. 3.247; 48/109 (SCIE); 33/88 (SSCI); 73/172 (SCIE); 6
77. **Rose AJ (PI)**, McBain R (C), Schuler MS (C), LaRochelle MR (C), Ganz DA (C), Kilambi V (C), Stein BD (C), Bernson D (C), Chui KKH (C), Land T (C), Walley AY (C), Stopka TJ (PI). Effect of age on opioid prescribing, overdose, and mortality in Massachusetts, 2011 to 2015. *J Am Geriatric Soc*. 2019;67:128-132. DOI: 10.1111/jgs.15659. 7.538; 10/54 (SCIE); 2/37 (SSCI); 24
78. **Rose AJ (PI)**, Timbie JW (C), Setodji C (C), Friedberg MW (C), Malsberger R (T), Kahn KL (PI). Primary care visit regularity and patient outcomes: an observational study. *J Gen Intern Med*.

- 2019;34:82-89. DOI: 10.1007/s11606-018-4718-x.
6.473; 11/109; 31/172; 9
79. **Rose AJ (C)**, Bayliss E (C), Baseman L (T), Butcher E (T), Huang W (C), Edelen MO (PI). Feasibility of distinguishing performance among provider groups using patient-reported outcome measures in older adults with multiple chronic conditions. *Med Care*. 2019;57:180-186. 3.178; 49/109 (SCIE); 34/88 (SSCI); 109/210 (SCIE); 5
 80. Stopka TJ (PI), Amaravadi H (C), Kaplan AR (C), Hoh R (C), Bernson D (C), Chui KKH (C), Land T (C), Walley AY (C), LaRochelle MR (C), **Rose AJ (PI)**. Opioid overdose deaths and potentially inappropriate opioid prescribing practices (PIP): A spatial epidemiological study. *Int J Drug Policy*. 2019;68:37-45. 5.931; 5/37 (SSCI); 30
 81. Larochelle MR (C), Bernstein R (C), Bernson D (C), Land T (C), Stopka TJ (PI), **Rose AJ (C)**, Bharel M (C), Liebschutz JM (C), Walley AY (C). Touchpoints – opportunities to predict and prevent opioid overdose: a cohort study. *Drug Alcohol Depend*. 2019;204:107537. doi: 10.1016/j.drugalcdep.2019.06.039. 4.852; 61/155 (SCIE); 44/143 (SSCI); 6/21 (SCIE); 8/37 (SSCI); 70
 82. Jasuja GK (PI), Engle RL (C), Skolnik A (C), **Rose AJ (C)**, Male A (C), Reisman J (T), Bokhour BG (C). Understanding the Context of High- and Low-Testosterone Prescribing Facilities in the Veterans Health Administration (VHA): A Qualitative Study. *J Gen Intern Med*. 2019;34:2467-2474. doi: 10.1007/s11606-019-05270-6. 6.473; 11/109; 31/172; 2
 83. **Rose AJ (PI)**, Goldberg R (C), McManus DD (C), Kapoor A (C), Wang V (C), Liu W (C), Yu H (PI). Anticoagulant prescribing for non-valvular atrial fibrillation in the Veterans Health Administration. *J Am Heart Assoc*. 2019;8:e012646. PMID: 31441364. 6.107; 42/143; 15
 84. McBain RK (PI), Sousa JL (C), **Rose AJ (C)**, Baxi SM (C), Faherty LJ (C), Taplin C (C), Chappel A (C), Fischer SH (PI). Impact of project ECHO models of medical tele-education: A systematic review. *J Gen Intern Med*. 2019;34:2842-2857. doi: 10.1007/s11606-019-05291-1. 6.473; 11/109; 31/172; 51
 85. Faherty LJ (C), **Rose AJ (C)**, Chappel A (C), Taplin C (C), Martineau M (T), Fischer SH (PI). Assessing and expanding the evidence base for Project ECHO and ECHO-like models: Findings of a technical expert panel. *J Gen Intern Med*. 2020;35:899-902. 6.473; 11/109; 31/172; 17

Subsequent to appointment at HUJI-----

86. Rongali S (S), **Rose AJ (C)**, McManus DD (C), Bajracharya AS (C), Kapoor A (C), Granillo E (C), Yu H (PI). Learning Latent Space Representations to Predict Patient Outcomes: Model Development and Validation. *J Med Internet Res*. 2020; 22(3):e16374. PMID: 32202503. 7.077; 10/109; 5/31; 6
87. Ko D (S), Kapoor A (C), **Rose AJ (C)**, Hanchate A (C), Miller DR (C), Winter MR (C), Palmisano JN (C), Henault L (T), Walkey AJ (C), Tripodis Y (C), Karcz A (C), Hylek EM (PI). Temporal Trends in Pharmacologic Prophylaxis for Venous Thromboembolism after Hip and Knee Replacement in Older Adults. *Vasc Med*. 2020;25:450-459. 4.739; 24/67; 0
88. Jasuja GK (PI), DeGroot A (T), Quinn EK (T), Ameli O (T), Hughto JMW (C), Dunbar M (C), Deutsch M (C), Streed CG (C), Paasche-Orlow MK (C), Wolfe HL (C), **Rose AJ (PI)**. Beyond gender identity disorder diagnosis codes: An examination of additional methods to identify transgender individuals in administrative databases. *Med Care*. 2020;58:903-911. 3.178; 49/109 (SCIE); 34/88 (SSCI); 109/210 (SCIE); 9

89. Jasuja GK (PI), Bettano A (C), Smelson D (C), Bernson D (C), **Rose AJ (C)**, Byrne T (C), Berlowitz DR (C), McCullough M (C), Miller DR (C). Homelessness and Veteran Status in Relation to Nonfatal and Fatal Opioid Overdose in Massachusetts. *Med Care*. 2021;59(Suppl 2):S165-S169. 3.178; 49/109 (SCIE); 34/88 (SSCI); 109/210 (SCIE); 2
90. Shetty KD (C), Chen AY (C), **Rose AJ (C)**, Liu HH (PI). Effect of the ExactCare medication care management model on adherence, health care utilization, and costs. *J Manag Care Spec Pharm*. 2021;27(5):574-585. doi: 10.18553/jmcp.2021.20431. 2.338; 75/109; 215/279; 0
91. **Rose AJ (PI)**, Dunbar MS (C), Hughto JMW (C), Jasuja GK (PI). Conceptual approach to developing quality measures for transgender patients. *BMC Health Serv Res*. 2021;21:152. <https://doi.org/10.1186/s12913-021-06161-5>. 2.908; 63/109; 0
92. Hughto JMW (PI), Quinn EK (T), Dunbar MS (C), **Rose AJ (C)**, Shireman TI (C), Jasuja GK (PI). Prevalence and Co-occurrence of Alcohol, Nicotine, and Other Substance Use Disorder Diagnoses Among US Transgender and Cisgender Adults. *JAMA Netw Open*. 2021;4(2):e2036512. doi:10.1001/jamanetworkopen.2020.36512. 13.360; 15/172; 29
93. Peterson GG (PI), Pu J (C), Magid DJ (C), Barterian L (C), Kranker K (C), Barna M (C), Conwell L (C), **Rose A (C)**, Blue L (C), Markovitz A (C), McCall N (PI), Markovich P (C). Effect of the Million Hearts Cardiovascular Disease Risk Reduction Model on Initiating and Intensifying Medications: A Prespecified Secondary Analysis of a Randomized Clinical Trial. *JAMA Cardiol*. 2021;6(9):1050-1059. doi:10.1001/jamacardio.2021.1565. 30.157; 4/143; 5
94. **Rose AJ (PI)**, Hughto JMW (C), Dunbar MS (C), Quinn EK (T), Deutch M (C), Feldman J (C), Radix A (C), Safer JD (C), Shipherd JC (C), Thompson J (C), Jasuja GK (PI). Trends in Feminizing Hormone Therapy for Transgender Patients, 2006-2017. *Transgender Health*. epub ahead of print. <https://doi.org/10.1089/trgh.2021.0041>. 4.427; 36/131 (SSCI); 76/210 (SCIE); 48/182 (SSCI); 8/46 (SSCI); 1
95. **Rose AJ (P)**, Lee JS (C), Berlowitz DR (C), Liu W (C), Mitra A (C), Yu H (PI). Guideline-Discordant Dosing of Direct-Acting Oral Anticoagulants in the Veterans Health Administration. *BMC Health Serv Res*. 2021; 21(1):1351. doi: 10.1186/s12913-021-07397-x. 2.908; 63/109; 0
96. Sanghai SR (S), Liu W (C), Wang W (C), Rongali S (C), Orkaby AR (C), Saczynski JS (C), **Rose AJ (C)**, Kapoor A (C), Li W (C), Yu H (C), McManus DD (PI). Prevalence of frailty and associations with oral anticoagulant prescribing in atrial fibrillation. *J Gen Intern Med*. 2022;37:730-6. doi: 10.1007/s11606-021-06834-1. 6.473; 11/109; 31/172; 5
97. Dunbar MS (C), Hughto JMW (C), Jasuja GK (PI), Quinn EK (T), Deutsch M (C), Radix A (C), Feldman J (C), Abbott J (C), Safer JD (C), Thompson J (C), **Rose AJ (PI)**. Considering quality measures for the care of transgender patients: Preliminary findings from a technical expert panel. *LGBT Health*. 2022;9:264-275. doi: 10.1089/lgbt.2021.0279. 5.150; 59/210 (SCIE); 34/182 (SSCI); 0
98. Restar A (C), Dusic E (C), Garrison-Desany H (C), Lett E (C), Everhart A (C), Baker K (C), Scheim A (C), Beckham SW (C), Reisner S (C), **Rose A (C)**, Mimiaga M (C), Radix A (C), Operario D (C), Hughto J (PI). (2022) Gender Affirming Hormone Therapy Dosing Behaviors among Transgender and Nonbinary Adults. *Human Soc Sci Commun*. 2022;9:304. <https://doi.org/10.1057/s41599-022-01291-5>. 2.731; 37/112 (SSCI); 0
99. **Rose AJ (PI)**, Ein Mor E (C), Krieger M (C), Ben-Yehuda A (C), Cohen A (C), Matz E (C), Bar Ratson E (C), Bareket R (C), Paltiel O (C), Calderon-Margalit R (PI). Israeli COVID lockdowns mildly reduced overall use of preventive health services, but exacerbated some disparities. *Int J*

Qual Health Care. 2022; 34(3):mzac071. doi: 10.1093/intqhc/mzac071. 2.257; 81/109 (SSCI); 0

100. Engle RL (C), Bokhour BG (C), **Rose AJ (C)**, Reisman JI (T), Jasuja GK (PI). Characterizing Patient Attitudes and Beliefs Towards Testosterone Therapy in Veterans Affairs: A Qualitative Study. *Patient Educ Couns*. (2023); 106:201-207. doi: 10.1016/j.pec.2022.10.003. 3.467; 99/210 (SCIE); 22/112 (SSCI); 0
101. Pikkal Geva HZ (S), Gershgoren H (C), Nir D (C), Khazen M (C), **Rose AJ (PI)**. Vaccine hesitancy among health care workers in the era of COVID-19. *Health Education Research*. In press.

MULTICENTER STUDIES

None

CASE REPORTS

1. Wasserman MS (S), **Rose AJ (PI)**. An Unusual Presenting Complaint for Herpes Zoster. *Am J Med*. 2013; 126:e3-e4. DOI: 10.1016/j.amjmed.2013.01.015. 5.928; 36/172; 0

LETTERS

1. **Rose A (PI)**. Letter in Response to: Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. *N Engl J Med*. 2011;365:2333-2334. 176.082; 2/172; 6
2. **Rose AJ (PI)**. Letter in Response to: Pappas et al, Cost-Effectiveness of Bridging Anticoagulation. *J Gen Intern Med*. 2021;36(1):225. <https://doi.org/10.1007/s11606-019-05321-y>. 6.473; 11/109; 31/172; 0

REVIEWS, COMMENTARIES, HYPOTHESES, EDITORIALS

1. **Rose AJ (S)**, Berlowitz DR (PI), Frayne SM (C), Hylek EM (C). Measuring Quality of Oral Anticoagulation Care: Extending Quality Measurement to a New Field. *Jt Comm J Qual Patient Saf*. 2009; 35:146-55. DOI: 10.1016/S1553-7250(09)35019-9. X; X; 21
2. Hylek EM (PI), **Rose AJ (S)**. Understanding Low INR in Clinical Practice. *Thromb Haemost*. 2009;101:417-8. DOI:10.1160/TH09-01-0067. 6.830; 18/78; 12/67; 2
3. **Rose AJ (PI)**. Patient Education: The Missing Link in Improving Quality of Oral Anticoagulation. *Cardiology*. 2010;116:59-60. DOI: 10.1159/000314935. 2.342; 103/143; 3
4. **Rose AJ (S)**, Hylek EM (PI). High blood pressure while taking antithrombotic medication is associated with an increased risk of developing intracranial haemorrhage. *BMJ Evid-Based Med*. 2010; 15(6):189-190. DOI: 10.1136/ebm1123. 5.696; 42/172; 0
5. **Rose AJ (PI)**. Improving the Management of Warfarin May Be Easier Than We Think. *Circulation*. 2012;126:2277-2279. DOI: 10.1161/CIRCULATIONAHA.112.141887. 39.922; 2/143; 1/67; 7
6. **Rose AJ (PI)**, Hylek EM (C), Berlowitz DR (C). Measuring and Improving Quality of Oral Anticoagulation for Veterans. *Federal Practitioner*. 2013; Oct 4;34-6. X; X; 0
7. **Rose AJ (PI)**. Warfarin: Not Dead Yet. *J Gen Intern Med*. 2014;29:425-6. DOI: 10.1007/s11606-013-2708-6. 6.473; 11/109; 31/172; 1

8. Sarrazin MSV (PI), **Rose AJ (C)**. Safety of new oral anticoagulants. *BMJ*. 2015; 350:h1679. Doi: 10.1136/bmj.h1679. 96.216; 4/172; 8
9. **Rose AJ (PI)**. What We Aren't Measuring Yet: Applying Quality Measurement More Broadly. *J Gen Intern Med*. 2016;31:821-2. DOI: 10.1007/s11606-016-3714-2. 6.473; 11/109; 31/172; 3
10. **Rose AJ (PI)**, Allen AL (C), Minichello T (C). A call to reduce the use of bridging anticoagulation. *Circ Cardiovasc Qual Outcomes*. 2016;9:64-7. DOI: 10.1161/CIRCOUTCOMES.115.002430. 8.271; 24/143; 17
11. **Rose A (PI)**. Patients with severe schizophrenia aren't getting the help they need. *Health Affairs Blog*. July 25, 2016. X; X; 0
12. **Rose AJ (PI)**. Flying Blind: Don't Manage Warfarin Without a Registry. *Jt Comm J Qual Patient Safety*. 2017;43:351-2. DOI: 10.1016/j.jcjq.2017.03.005. X; X; 0
13. **Rose AJ (PI)**. Targeted Approaches to Improve Outcomes for Highest-Cost Patients. *Isr J Health Policy Res*. 2017;6:25. DOI: 10.1186/s13584-017-0151-6. 2.465; 55/88 (SSCI); 114/182 (SSCI); 0
14. **Rose A (PI)**, Hussey P (C), Martineau M (C), Friedberg M (C). Improving MACRA's chances of success. *The Health Care Blog*: January 6, 2017. X; X; 0
15. Jasuja GK (PI), Bhasin S (C), **Rose AJ (PI)**. Patterns of Testosterone Prescription Overuse. *Curr Opin Endocrinol Diabetes*. 2017;24:240-5. DOI: 10.1097/MED.0000000000000336. 3.626; 86/146; 20
16. **Rose AJ (PI)**, McCullough MB (C), Carter BL (C), Rudin RS (C). The clinical pharmacy specialist: part of the solution. *J Gen Intern Med*. 2017;32:375-7. DOI: 10.1007/s11606-016-3958-x. 6.473; 11/109; 31/172; 7
17. **Rose AJ (PI)**, McCullough MB (C). A Practical Guide to Using the Positive Deviance Method in Health Services Research. *Health Serv Res*. 2017;52:1207-22. DOI: 10.1111/1475-6773.12524. 3.734; 35/109 (SCIE); 21/88 (SSCI); 34
18. Fischer S (PI), **Rose A (PI)**. Responsible e-prescribing needs e-discontinuation. *JAMA*. 2017;317:469-70. DOI: 10.1001/jama.2016.19908. 157.375; 3/172; 12
19. **Rose AJ (PI)**, Fischer SH (C), Paasche-Orlow MK (PI). Beyond medication reconciliation: The correct medication list. *JAMA*. 2017;317:2057-8. DOI: 10.1001/jama.2017.4628. 157.375; 3/172; 50
20. **Rose AJ (PI)**, McCullough MB (C), Jasuja GK (C). A Three-Step Health Services Research Approach to Improve Prescribing. *Healthcare: The Journal of Delivery Science and Innovation*. 2018;6:135-138. DOI: 10.1016/j.hjdsi.2017.10.002. 3.160; 50/109 (SCIE); 35/88 (SSCI); 0
21. McBain R (PI), **Rose AJ (C)**, LaRochelle MR (C). The US Opioid Epidemic: One Disease, Diverging Tales. *Prev Med*. 2018;112:176-178. doi:10.1016/j.ypmed.2018.04.023. 4.637; 56/172; 69/210; 9
22. **Rose AJ (PI)**, Vaiana M (C). Evidence-based Best Practices for Outpatient Management of Warfarin. *Ann Pharmacother*. 2018;52:1042-1046. DOI: 10.1177/1060028018782473. 3.463; 148/279; 0

Subsequent to appointment at HUJI-----

23. **Rose AJ (PI)**, Ellen ME (PI). COVID-Related Disruption: Finding the Silver Lining. *J Gen Intern Med*. 2020;35:3361-3362. 6.473; 11/109; 31/172; 1

24. **Rose AJ (PI)**, Witt D (C), Azran C (C), Nissan R (C). Seven Key Parameters that Facilitate Clinical Pharmacy Practice: A Comparison Between Israel and the United States. *Isr J Health Policy Res.* 2021;10:37. 2.465; 55/88 (SSCI); 114/182 (SSCI); 2

OTHER PUBLICATIONS (Reports, instruction manuals, online resources, teaching aids etc.)

1. **Rose AJ (PI)**, Hylek EM (C), Ozonoff A (C), Ash AS (C), Reisman JI (T), Berlowitz DR (PI). Percent Time in Therapeutic Range. A quality indicator listed by the AHRQ National Quality Measures Clearinghouse. Release Date: July 2010. (X,X,X)
2. Edelen MO (PI), Gage B (C), **Rose AJ (C)**, Ahluwalia S (C), DeSantis ASJ (C), Dunbar MS (C), Fischer SH (C), Huang W (C), Klein DJ (C), Martino S (C), Pillemer F (C), Piquado T (C), Shier V (C), Shih RA (C), Sherbourne CD (C), Stucky B (C). RAND Report 1895. 2017. "Findings From Alpha 1 Pilot Testing: Summary Report". PMID: 29416941 (X,X,X)
3. Kazis LE (PI), Rogers W (C), Rothendler J (C), Qian S (C), Selim A (C), Edelen MO (C), Stucky B (C), **Rose A (C)**, Butcher E (T). RAND Report 1844. 2017. "Outcome Performance Measure Development for Persons with Multiple Chronic Conditions." (X,X,X)
4. Edelen MO (PI), **Rose AJ (C)**, Bayliss E (C), Baseman L (T), Butcher E (T), Garcia RE (C), Tabano D (C), Stucky BD (C). RAND Report 2176. 2017. "Patient-Reported Outcome-Based Performance Measures for Older Adults with Multiple Chronic Conditions". DOI: 10.7249/RR2176 (X,X,X)
5. Conwell L (C), Barterian L (C), **Rose A (C)**, Peterson G (C), Kranker K (C), Blue L (C), Magid D (C), Williams M (C), Steiner A (C), Sarwar R (C), Tyler J (C), Brand E (C), Barna M (C), Kinber D (C), Fu N (C), Concannon T (C), McCall N (PI). Evaluation of the Million Hearts Cardiovascular Disease Risk Reduction Model: First Annual Report. October 26, 2018. Report by Mathematica Policy Research to CMS. (X,X,X)
6. Fischer SH (PI), **Rose AJ (PI)**, McBain RK (C), Faherty LJ (C), Sousa J (T), Martineau M (T). RAND Report 2934. 2019. "Evaluation of Technology-Enabled Collaborative Learning and Capacity Building Models: Materials for a Report to Congress." (X,X,X)

Subsequent to appointment at HUJI-----

7. Mendel P (PI), Gidengil CA (C), Tomoaia-Cotisel A (C), Mann S (C), **Rose AJ (C)**, Leuschner KJ (T), Qureshi NS (T), Karedy V (T), Sousa J (T), Kim D (T). "Health Services and Primary Care Research Study: Comprehensive Report." Santa Monica, CA: RAND Corporation, 2020. https://www.rand.org/pubs/research_reports/RR3229.html. (X,X,X)
8. Meadows SO (PI), Engel CC (PI), Collins RL (C), Beckman RL (C), Breslau J (C), Bloom EL (C), Dunbar MS (C), Gilbert ML (C), Grant D (C), Hawes-Dawson J (C), Holliday SB (C), MacCarthy S (C), Pedersen ER (C), Robbins MW (C), **Rose AJ (C)**, Ryan J (C), Schell TL (C), Simmons MM (C). 2018 Department of Defense Health Related Behaviors Survey (HRBS). Santa Monica, CA: RAND Corporation, 2021. (X,X,X)

PATENTS

None

CONFERENCES

Invited lectures

1. Chief Residents' Immersion Training (CRIT) Program, Boston University. How to Publish Your

CRIT Project. 2007

2. Grand Rounds, Boston University School of Medicine, Section of General Internal Medicine. "Hypertension Therapy Intensification for Patients with Suboptimal Adherence: Is it Beneficial?" 2009
3. Visiting Lecture, Kaiser Permanente Colorado, Aurora CO. "Measuring and Improving Quality of Oral Anticoagulation." 2011
4. Guest Lecture, HM 837, Boston University School of Public Health (Course Title: Measuring Quality of Healthcare). "Measuring Quality of Oral Anticoagulation Care". I gave this lecture annually from 2011-2016.
5. Fellowship in General Internal Medicine, Boston University. "How to Write a Research Paper". 2011
6. Medical Residents, Boston University School of Medicine. "You CAN Do Research". 2012
7. Grand Rounds, VA Boston Healthcare System. "Anticoagulation Therapy in the VA". 2012
8. Beth Israel Deaconess Medical Center, Section of General Internal Medicine, Grand Rounds. "Measuring and Improving the Quality of Oral Anticoagulation". 2012
9. Boston University School of Medicine. Section of General Internal Medicine, Grand Rounds. "Measuring and Improving the Quality of Oral Anticoagulation". 2013
10. Boston University School of Medicine. Symposium on Large Database Research. "Measuring and Improving Quality of Care Using Large Databases". 2013
11. Medical Residents, Boston University School of Medicine. "You CAN Do Research". 2014
12. Fellowship in General Internal Medicine, Boston University. "How to Write a Grant Proposal". 2014
13. Fellowship in General Internal Medicine, Boston University. "How to Write a Career Development Award Proposal". 2015
14. Fellowship in General Internal Medicine, Boston University. "How to Write a Research Paper". 2015
15. Fellowship in General Internal Medicine, Boston University. "How to Write a Research Paper". 2016
16. Fellowship in General Internal Medicine, Boston University. "How to Get the Most Out of Attending a National Meeting". 2016
17. Ben Gurion University School of Public Health. "Improving Medication Management: A Four-Step Approach". February 2018.
18. K Institute, Kfar Malal. "Timing of Primary Care Visits: A Quality Indicator, or Simply a Predictor of Patient Outcomes?". November 2021.
19. Physicians of Jerusalem Region Tipat Chalav, monthly conference. "Introduction to Implementation Science". January 2022.

Oral presentations

(*Indicates student/mentee authors)

1. **Rose AJ**, Shimada SL, Rothendler JA, Reisman JI, Glassman PA, Berlowitz DR, Kressin NR. The Accuracy of Clinician Perceptions of 'Usual' Blood Pressure Control. VA HSR&D, Baltimore, MD, USA. 2008.
2. **Rose AJ**, Ozonoff A, Henault LE, Hylek EM. Warfarin for Atrial Fibrillation in Community-Based Practice. Society of General Internal Medicine, Pittsburgh, PA, USA. 2008.
3. **Rose AJ**, Berlowitz DR, Manze M, Orner MB, Kressin NR. Treatment Intensification Improves Blood Pressure Control Both in Adherent and Non-Adherent Patients. Society of General Internal Medicine, Miami, FL. 2009.
4. Ozkaynak M* (presenter), **Rose AJ**, Johnson S, Tulu B. Understanding the Work System at Anticoagulation Clinics. Industrial and Systems Engineering Research Conference, Orlando, FL. 2012.
5. Benedict A* (presenter), **Rose AJ**, Park A, Fu A, Schlosser J. Evaluation of Multiple

- Anticoagulation Delivery Methods using Observations and Time Studies. Proceedings of Annual Industrial and Systems Engineering Research Conference, ISERC 2013, May 18-22, 2013, San Juan, Puerto Rico. 2013.
6. Ozkaynak M* (presenter), Johnson S, **Rose A**, Kanaan A, Donovan J, Tulu B. Preparing for the Worst: A Key for Better Anticoagulation Management. Proceedings of Annual Industrial and Systems Engineering Research Conference, ISERC 2013, May 18-22, 2013, San Juan, Puerto Rico. 2013.
 7. Efird L* (presenter), **Rose AJ**. Identifying the risks of oral anticoagulation in patients with liver disease. Society of General Internal Medicine, Denver, CO. 2013.
 8. Kim, EJ* (presenter), **Rose AJ**. Predicting Outcomes among Patients with Heart Failure Receiving Anticoagulation with Warfarin. American Heart Association Quality of Care and Outcomes Research Annual Meeting, Baltimore, MD. 2013.
 9. McCullough MB* (presenter), Solomon J, Petrakis BA, Park AM, **Rose AJ**. Clinical Pharmacists and Pharmaceutical Futures. American Anthropological Association Annual Meeting, Chicago, IL. 2013.
 10. McCullough, MB* (presenter), Solomon, J, Petrakis, BA, **Rose, AJ**. Middle managers, micro-practices and agency: Examining the dynamics between implementation and leadership in an anticoagulation care improvement initiative. Society for Medical Anthropology/ Society for Applied Anthropology Meetings, Albuquerque, NM. 2014.
 11. McCullough MB* (presenter), Gillespie C, Petrakis BA, Jones E, Park A, VanDeusen Lukas C, **Rose AJ**. Testing Implementation Strategies for Anticoagulation Improvement in Clinical Pharmacy Clinics: A Qualitative Study. 9th Annual Conference on the Science of Dissemination and Implementation Science Washington DC December 14-15, 2016.
 12. McCullough MB* (presenter), Gillespie C, Petrakis BA, Van Deusen Lukas C, **Rose AJ**. Forming and Activating an Internal Facilitation Group for Successful Implementation: A Qualitative Study. AcademyHealth Annual Research Meeting, Boston, MA. 2016.
 13. **Rose AJ**, Bayliss E, Baseman L, Butcher E, Huang W, Edelen MO. Distinguishing Performance Using Patient-Reported Outcomes. AcademyHealth Annual Research Meeting, Seattle, WA, June, 2018.

Posters

(*Indicates student/mentee authors)

1. **Rose AJ (S)**, Stein MR (C), Arnsten JH (C), Saitz R (PI). Teaching Internal Medicine Resident Physicians about Alcoholics Anonymous. Society of General Internal Medicine, Los Angeles, CA, USA. 2006.
2. **Rose AJ (S)**, Backus BM (T), Gershman ST (C), Santos P (C), Ash AS (C), Battaglia TA (PI). Predictors of Aggressive Therapy for Nonmetastatic Prostate Carcinoma in Massachusetts from 1998-2002. American Board of Preventive Medicine, Miami, FL, USA. 2007.
3. **Rose AJ (S)**, Berlowitz DR (C), Orner MB (C), Kressin NR (PI). Understanding Uncontrolled Hypertension: Is It the Patient or the Provider? Society of General Internal Medicine, Toronto, ON, Canada. 2007.
4. **Rose AJ (S)**, Hermos JA (C), Frayne SM (C), Pogach LM (C), Berlowitz DR (C), Miller DR (PI). Do Opioids Affect Quality of Care for Diabetes Mellitus? VA HSR&D, Baltimore, MD, USA. 2008.
5. **Rose AJ (S)**, Berlowitz DR (C), Manze M (T), Orner MB (T), Kressin NR (PI). Comparing Methods of Measuring Treatment Intensification in Hypertension Care. AcademyHealth, Chicago, IL, USA. 2009.
6. **Rose AJ (PI)**, Hylek EM (C), Ozonoff A (C), Ash AS (C), Reisman JI (T), Berlowitz DR (C). Patient-Level Predictors of Outpatient Anticoagulation Control. Society of General Internal Medicine, Minneapolis, MN, USA. 2010.
7. **Rose AJ (PI)**, Hylek EM (C), Ozonoff A (C), Ash AS (C), Reisman JI (T), Berlowitz DR (C). Risk-Adjusted Percent Time in Range as a Quality Indicator for Oral Anticoagulation Care. Society of

- General Internal Medicine, Minneapolis, MN, USA. 2010.
8. **Rose AJ (PI)**, Hylek EM (C), Ozonoff A (C), Ash AS (C), Reisman JI (T), Berlowitz DR (C). Prolonged Follow-Up Intervals Are Associated with Poorer Control in Outpatient Oral Anticoagulation. Society of General Internal Medicine, Minneapolis, MN, USA. 2010.
 9. Marrast L* (S, presenter), Henault LE (T), Hylek EM (PI), Evans M (S), Ozonoff A (C), **Rose AJ (PI)**. Factors Contributing to Extreme Warfarin Dose Variation. Presented at: 2010 Annual Meeting of the Society of General Internal Medicine, Minneapolis, MN. 2010.
 10. **Rose AJ (PI)**, Berlowitz DR (C), Hylek EM (C), Ash AS (C), Ozonoff A (C), Goldhaber-Fiebert JD (PI). Projected Benefits of Quality Improvement in Oral Anticoagulation for Patients with Atrial Fibrillation. VA HSR&D National Research Meeting, Washington, DC, USA. 2011.
 11. Ozkaynak M* (S, presenter), Tulu B (C), Kanaan A (C), Donovan J (C), **Rose A (C)**, Johnson S (PI). Informatics Opportunities for Better Anticoagulation Management. American Medical Informatics Association National Meeting, Chicago, IL. 2012.
 12. Kanaan AO* (C, presenter), Donovan JL (C), Ozkaynak M (S), Johnson S (PI), Tulu B (C), **Rose A (C)**. Integrating clinical pharmacists and industrial engineers' perspectives to develop a codebook to characterize structure at anticoagulation clinics. American College of Clinical Pharmacy National Meeting. Abstract published in *Pharmacotherapy* 2012;32(10):e225. 2012.
 13. Ambrus DB* (S, presenter), Reisman J (T), **Rose AJ (PI)**. Cancer type predicts outcomes of warfarin therapy. Society of General Internal Medicine, Denver, CO. 2013.
 14. Efird L* (S, presenter), **Rose AJ (PI)**. Identifying the risks of anticoagulation in patients with substance abuse. Society of General Internal Medicine, Denver, CO. 2013.
 15. Razouki Z* (S, presenter), **Rose AJ (PI)**. A new perspective in anticoagulation: Understanding time spent above and below the target range among patients receiving warfarin at the VA health care system. Society of General Internal Medicine, Denver, CO. 2013.
 16. Mantha S (S, presenter), **Rose A (C)**, Moll S (PI). Predicting time in the therapeutic range: a Bayesian approach. American Society of Hematology, New Orleans, LA. 2013.
 17. McCullough MB* (C, presenter), Benzer J (C), Charms M (C), **Rose AJ (PI)**. Saying yes but meaning no: Middle manager avoidant leadership strategies in the implementation of an evidence-based intervention. AcademyHealth Annual Meeting, San Diego, CA. 2014.
 18. Razouki Z* (S, presenter), **Rose AJ (PI)**. Comparing Warfarin Anticoagulation Measurements. Society of General Internal Medicine, San Diego, CA. 2014.
 19. McCullough MB* (C, presenter), Goren J (C), Male A (T), **Rose AJ (PI)**, Fix G (C). Practicing Beyond the Evidence: A Qualitative Analysis of Adoption and Dissemination of New Medications. 9th Annual Conference on the Science of Dissemination and Implementation Science Washington DC December 14-15. 2016.
 20. Pikkal HG* (S), Gershgoren H (S), Nir D (S), Khazan M (C), **Rose AJ (PI)**. Vaccine Hesitancy Among Health Care Providers. Hebrew University School of Public Health Alumni Day Poster Session. Jerusalem, Israel. 2022.

SCIENTIFIC BIOGRAPHY

1. PAST WORK

I completed medical school at the University of Pennsylvania in 2001 and Internal Medicine internship and residency at Montefiore Medical Center in 2004. From 2004-2005, I served as a chief resident at Montefiore, a role that focused on teaching and curriculum development. I continued to work part-time as a primary care doctor from 2005-2019.

In 2005, I began a fellowship in General Internal Medicine at Boston University. This postdoctoral research fellowship focused on teaching research skills and preparing me for an academic career as a researcher. Concurrently, I completed a second residency in Preventive Medicine, which is similar training to what physicians receive in Israel when they specialize in Public Health. During this time, I also completed an MSc degree in Health Services Research at the Boston University School of Public Health. My early projects focused on improving the management of hypertension and anticoagulation. My residency and degree ended in 2007. From 2007-2008, I stayed for a third year of fellowship, to increase my publications and write a career development grant.

In 2008, I was hired by the Bedford VA Medical Center, to work as a part-time physician and a full-time health services researcher in their research center of excellence. I was also appointed as an Assistant Professor of Medicine at Boston University, and was promoted to Associate Professor in 2013.

At the time of my hiring at the Bedford VA Medical Center, I received a 5-year career development grant from the US Department of Veterans Affairs (VA), Health Services Research and Development Service. This grant covered 100% of my salary for 5 years and allowed me to focus on building my career. In the project for my career development grant, I profiled 130 VA medical centers on their level of anticoagulation control. From this grant, as well as related follow-up grants, I embarked on a ten-year body of work that created an entire regime of quality measurement for anticoagulation management, including measures of structure, process, and outcomes of care. This work used different methods, including large database research, mixed methods, case mix adjustment, and ultimately, implementation science, as we pilot tested best practices in the New England region of VA. This work led to over 50 publications, was awarded approximately \$5 million in funding over 10 years, and led to a marked change in how the VA measures quality of care in outpatient oral anticoagulation to this day. In 2015, as a crowning achievement to this work, I led the writing of a new VA National Anticoagulation Directive, the document that governs how this therapy is managed and how quality assurance is performed. As a result of this work, anticoagulation control in VA improved markedly, which can be expected to prevent hundreds of adverse or fatal events. This work also had a profound influence on anticoagulation management outside VA. In recognition of this body of work, I was awarded the Presidential Early Career Award in Science and Engineering in early 2017.

During this time, I also increased my presence as a mentor. From 2011-2016, I supervised six internal medicine residents, who wrote their first paper under my tutelage (publications # 10, 15, 23, 32, 34, 27, 44, 58). I advised three postdoctoral fellows in Internal Medicine (publications #33, 36, 40, 43, 54, 56). I advised three PhD postdoctoral fellows (publications # 28, 31, 41, 42, 46, 47). Many of these advisees have continued to academic careers of their own. For this work, I received the Junior Faculty Mentoring Award from Boston University's Department of Internal Medicine in 2013.

In 2014, I was named Director of the Medication Optimization Program, one of three topical areas within my research center at the VA. In this role, I coordinated medication-related research among a group of approximately 20 researchers, and strategically planned how our group could increase grant funding and publications together. This role led to my role in multiple efforts to improve prescribing of diverse medications, including opioids, testosterone, vasodilators, antipsychotics, and others.

In 2016, I moved from the VA to the RAND Corporation, a non-profit research organization which performs work supported by grants (investigator-initiated) and contracts (often for the US Government). My work at RAND allowed me an opportunity to broaden my scope to include health policy analysis, and to work on different issues and on important evaluations of the impact of large government programs. Among the highlights were my involvement with the evaluation of the Medicare Million Hearts Program, an effort to use pay for performance to incentivize better cardiac risk reduction. In this project, I co-led the qualitative evaluation of participating sites. I also participated in the Military Health Related Behaviors Survey, as a co-lead for the preventive medicine and physical symptoms content areas. I was co-PI of an effort to evaluate the impact of Project ECHO (Extension for Community Healthcare Outcomes), an increasingly popular approach to supporting generalist physicians with specialist mentoring to handle more complex problems. For this project, we produced a report that was used as part of a report to the US Congress. I also participated in an ambitious effort to evaluate the current state of health services research in the United States, and led the team that enumerated all the existing projects using machine learning. While my VA research had been practical and impactful, RAND pushed me to become ever more flexible about content areas and research methods, and to solve research problems that initially seemed unsolvable. RAND also greatly increased the scope of clinical and policy topics I addressed, from my previous focus on medications (which is already broad) to encompass nearly any topic that relates to clinical medicine and health services research.

2. PRESENT ACTIVITIES

In 2019, I left my job at RAND because my family had decided to move to Israel. I spent the 2019-2020 year learning Hebrew and activating my Israeli medical license, including a three-month observation in Internal Medicine at Hadassah Ein Kerem.

In July 2020, I began as an Associate Professor of Public Health at Hebrew University. Since arriving, I have been assiduously writing grant proposals and working to become an integral part of my new school. I have discovered that I enjoy teaching very much, and currently teach a course in the fall, another in the spring, and co-teach a seminar for Masters' Theses in the Spring. I am currently supervising multiple masters' theses, and serve as the advisor for multiple masters' papers each year.

In October 2021, I began a three-year research project, funded by the ISF. We are using data from Leumit to examine how the timing of primary care visits may impact patient outcomes. In a second part of the study, we are performing qualitative interviews and site visits to understand how different clinics within the Leumit system are more or less effective at keeping patients engaged in care and promoting more regular primary care visits. This work is expected to lead to concrete recommendations for Leumit, and other Israeli HMOs, to work to increase the regularity of primary care visits to promote more proactive and effective care. Maram Hazen PhD, PharmD joined this project as a postdoctoral fellow. We are wrapping up our work with the database study, and are well into data collection from qualitative site visits to 10 Leumit clinics.

In June 2022, I began two projects funded by the Israel Institute of Health Policy Research. The first addresses a longstanding issue in Israeli healthcare, namely that hospitals are paid per patient-day and there is no differential payment for case complexity. We will use both a standard risk adjustment model and an enhanced version of the model to account for case complexity and will demonstrate its utility for predicting outcomes, differential payment according to case mix, and selection of low-risk patients for home hospitalization. My co-PI for this project is the HUJI health economist Shuli Brammli-Greenberg; our partner at Shaarei Zedek is David Katz, the director of Internal Medicine A.

The second project addresses a problem in psychiatric emergency departments (ED) in Israel. Under

current policy, patients cannot be admitted involuntarily until the senior psychiatrist sees them in person. This leads to the patient waiting in the ED, and often results in their decompensation and in violent incidents. We will use an iPad to conduct a virtual interview, with approval from the Ministry of Health. We will measure patient outcomes, and expect to find that patients spend less time in the ED and have fewer violent events. If the study is successful, we expect it to lead to a permanent change in policy in Israel. My co-PI for this study is the noted Israeli psychiatrist Renana Eitan, director of Psychiatry at Ichilov.

I have recently begun an unfunded study, in partnership with Shmuel Klang, head of the Research Institute at Meuhedet. This project will compare several different measures of medication adherence that are currently in use for research and quality improvement. These measures have not previously been compared head-to-head regarding their ability to predict outcomes such as blood pressure control or hospitalizations. We will compare them here, which will lead to concrete recommendations about which measure is preferred for future use.

3. FUTURE PLANS

I am working on research proposals with partners based in Australia (to study management of hypertension) and the US (to study cardiovascular risk prediction, to study different treatment strategies for male osteoporosis, to study predictors of blood pressure control).

I am also supervising eight Masters' theses, all of which I expect will lead to publications. I will continue to look for opportunities to submit proposals for additional work, including with partners from other schools in Israel. My goal is to do most of my work in the local environment (Israel), to enhance my ties with my local investigators and to have an impact locally. At the same time, I will maintain my connections with US-based researchers, which have been so productive for me until today.

Explanation of Contribution to Recent Publications (after appointment to HUJI):

Rongali S (S), **Rose AJ (C)**, McManus DD (C), Bajracharya AS (C), Kapoor A (C), Granillo E (C), Yu H (PI). Learning Latent Space Representations to Predict Patient Outcomes: Model Development and Validation. *J Med Internet Res*. 2020; 22(3):e16374. PMID: 32202503.

Contributed to study design and manuscript writing.

Ko D (S), Kapoor A (C), **Rose AJ (C)**, Hanchate A (C), Miller DR (C), Winter MR (C), Palmisano JN (C), Henault L (T), Walkey AJ (C), Tripodis Y (C), Karcz A (C), Hylek EM (PI). Temporal Trends in Pharmacologic Prophylaxis for Venous Thromboembolism after Hip and Knee Replacement in Older Adults. *Vascular Medicine*. 2020;25:450-459.

Contributed to obtaining funding, led data abstraction team, contributed to analysis and manuscript writing.

Jasuja GK (PI), DeGroot A (T), Quinn EK (T), Ameli O (T), Hughto JMW (C), Dunbar M (C), Deutsch M (C), Streed CG (C), Paasche-Orlow MK (C), Wolfe HL (C), **Rose AJ (PI)**. Beyond gender identity disorder diagnosis codes: An examination of additional methods to identify transgender individuals in administrative databases. *Med Care*. 2020;58:903-911.

Obtained funding, led analytic decisions, supervised study, co-wrote manuscript.

Jasuja GK (PI), Bettano A (C), Smelson D (C), Bernson D (C), **Rose AJ (C)**, Byrne T (C), Berlowitz DR (C), McCullough M (C), Miller DR (C). Homelessness and Veteran Status in Relation to Nonfatal and Fatal Opioid Overdose in Massachusetts. *Med Care*. 2021;59(Suppl 2):S165-S169.

Contributed to study design, analysis, manuscript writing.

Shetty KD (C), Chen AY (C), **Rose AJ (C)**, Liu HH (PI). The impact of the ExactCare medication management model on adherence, healthcare utilization, and costs. *Journal Manag Care and Spec Pharm*. 2021;27(5):574-585. doi: 10.18553/jmcp.2021.20431.

Contributed to obtaining funding, study design, analysis, manuscript writing.

Rose AJ (PI), Dunbar MS (C), Hughto JMW (C), Jasuja GK (PI). Conceptual approach to developing quality measures for transgender patients. *BMC Health Services Research*. 2021;21:152. <https://doi.org/10.1186/s12913-021-06161-5>

Obtained funding, designed study, drafted manuscript.

Hughto JMW (C), Quinn EK (T), Dunbar MS (C), **Rose AJ (PI)**, Shireman TI (C), Jasuja GK (PI). Prevalence and Co-occurrence of Alcohol, Nicotine, and Other Substance Use Disorder Diagnoses Among US Transgender and Cisgender Adults. *JAMA Netw Open*. 2021;4(2):e2036512. doi:10.1001/jamanetworkopen.2020.36512

Obtained funding, supervised study, contributed to manuscript.

Peterson GG (PI), Pu J (C), Magid DJ (C), Barterian L (C), Kranker K (C), Barna M (C), Conwell L (C), **Rose A (C)**, Blue L (C), Markovitz A (C), McCall N (PI), Markovich P (C). Effect of the Million Hearts Cardiovascular Disease Risk Reduction Model on Initiating and Intensifying Medications: A

Prespecified Secondary Analysis of a Randomized Clinical Trial. *JAMA Cardiol.* 2021;6(9):1050-1059. doi:10.1001/jamacardio.2021.1565

Contributed to study design, analysis, manuscript.

Sanghai SR (S), Liu W (C), Wang W (C), Rongali S (C), Orkaby AR (C), Saczynski JS (C), **Rose AJ (C)**, Kapoor A (C), Li W (C), Yu H (C), McManus DD (PI). Prevalence of frailty and associations with oral anticoagulant prescribing in atrial fibrillation. *J Gen Intern Med.* 2022; 37(4): 730-6. doi: 10.1007/s11606-021-06834-1.

Contributed to study design, analysis, manuscript.

Rose AJ (PI), Hughto JMW (C), Dunbar MS (C), Quinn EK (T), Deutch M (C), Feldman J (C), Radix A (C), Safer JD (C), Shipherd JC (C), Thompson J (C), Jasuja GK (PI). Trends in Feminizing Hormone Therapy for Transgender Patients, 2006-2017. *Transgender Health*: epub ahead of print. <http://doi.org/10.1089/trgh.2021.0041>

Obtained funding, supervised study, led analysis, drafted manuscript.

Rose AJ (PI), Lee JS (C), Berlowitz DR (C), Liu W (C), Mitra A (C), Yu H (PI). Guideline-Discordant Dosing of Direct-Acting Oral Anticoagulants in the Veterans Health Administration. *BMC Health Services Research.* 2021; 21(1):1351. doi: 10.1186/s12913-021-07397-x.

Developed study idea, led analysis, drafted manuscript.

Dunbar MS (C), Hughto JMW (C), Jasuja GK (PI), Quinn EK (T), Deutsch M (C), Radix A (C), Feldman J (C), Abbott J (C), Safer JD (C), Thompson J (C), **Rose AJ (PI)**. Considering quality measures for the care of transgender patients: Preliminary findings from a technical expert panel. *LGBT Health.* 2022;9(4):264-75. doi: 10.1089/lgbt.2021.0279

Obtained funding, supervised study, participated in data collection and analysis, contributed to manuscript.

Restar A (C), Dusic E (C), Garrison-Desany H (C), Lett E (C), Everhart A (C), Baker K (C), Scheim A (C), Beckham SW (C), Reisner S (C), **Rose A (C)**, Mimiaga M (C), Radix A (C), Operario D (C), Hughto J (PI). (2022) Gender Affirming Hormone Therapy Dosing Behaviors among Transgender and Nonbinary Adults. *Humanities & Social Sciences Communications.* 2022;9:304. <https://doi.org/10.1057/s41599-022-01291-5>

Contributed to study idea, analyses, and manuscript.

Rose AJ (PI), Ein Mor E (C), Krieger M (C), Ben-Yehuda A (C), Cohen A (C), Matz E (C), Bar Ratson E (C), Bareket R (C), Paltiel O (C), Calderon-Margalit R (PI). Israeli COVID lockdowns mildly reduced overall use of preventive health services, but exacerbated some disparities. *Int J Qual Health Care.* 2022; 34(3):mzac071. doi: 10.1093/intqhc/mzac071.

Contributed to study idea and analyses, led drafting of manuscript.

Engle RL (C), Bokhour BG (C), **Rose AJ (C)**, Reisman JI (T), Jasuja GK (PI). Characterizing Patient Attitudes and Beliefs Towards Testosterone Therapy in Veterans Affairs: A Qualitative Study. *Patient Education and Counseling* (2022). 022 Oct 10;S0738-3991(22)00446-3. doi: 10.1016/j.pec.2022.10.003

Contributed to study idea, study design, and manuscript.

Reviews or concept papers:

Rose AJ (PI), Ellen ME (PI). COVID-Related Disruption: Finding the Silver Lining. *J Gen Intern Med* 2020;35:3361-3362.

Co-developed the idea, drafted the manuscript.

Rose AJ (PI), Witt D (C), Azran C (C), Nissan R (C). Seven Key Parameters that Facilitate Clinical Pharmacy Practice: A Comparison Between Israel and the United States. *Isr J Health Policy Res* 2021;10:37.

Originated the idea, collected the team, performed the research, drafted the manuscript, supervised the study.